Cilla E. J. Vrinzen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cilla E. J. Vrinzen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Paulus Theodoor Jeurissen
Department of IQ Health, Radboud university medical center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands
15 shared publications - Haiko J. Bloemendal
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands
14 shared publications - Linn Delfgou
Scientific Institute for Quality of Healthcare, Radboudumc, Nijmegen, The Netherlands
14 shared publications - Matthias Adrianus Wilhelmus Merkx
Department of Oral and Maxillofacial Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands
14 shared publications - Niek Stadhouders
Science department IQ Health, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Health Economics, School of Business and Economics, Talma Institute, Vrije Universiteit, Amsterdam, The Netherlands
14 shared publications - Rosella Petronella Maria Gemma Hermens
Radboud University Medical Center
14 shared publications
Latest Publications
- Open Access
Comprehensive Cancer Networks in the Netherlands: how do they affect quality and costs of care for colon or pancreatic cancer? A retrospective cohort study
Objective: Concentration of care and collaborations between hospitals increasingly reorganise oncological care into Comprehensive Cancer Networks (CCNs), aiming to improve care outcomes and reduce costs. This study aims to evaluate the effect of four CCNs on healthcare cost and outcomes for patients with colon or pancreatic cancer. Design: We performed a retrospective cohort study based on claims data in the Netherlands. Data included patient characteristics, health insurance claims and healthcare activities. All costs were indexed to Euro 2023. We performed propensity score matching per CCN and applied regression models with a difference-in-difference design, adjusting for non-linear trends before the start of a CCN. Setting: The study was conducted within the Dutch healthcare system, analysing claims data representative of hospital-based cancer care. Participants: A total of 92 309 patients with colon cancer and 25 630 patients with pancreatic cancer were included. Patients were identified through health insurance claims between January 2013 and June 2021. Intervention: Implementation of four CCNs, which included structured collaboration between healthcare organisations. Follow-up duration was 2 years post-diagnosis. Outcome measures: Primary outcomes included 2-year oncological healthcare costs and 2-year mortality rate. Secondary outcomes involved care process indicators: referral rates and double diagnostics (an identical diagnostic activity performed within 4 weeks after referral to a secondary hospital). Results: For colon cancer, one CCN showed a significant decrease in 2-year oncological costs (−€1899). One CCN showed a significant decrease in referrals (−3.6%) and one a significant increase (+4.4%). No significant effect on 2-year mortality and double diagnostic activities was found. For pancreatic cancer, one CCN showed a significant decrease in 2-year oncological costs (−€3747) and one CCN showed a significant increase in double diagnostic activities (+8.6%). No significant effect on referrals and 2-year mortality was found. Conclusion: CCNs do not consistently reduce costs or affect referral patterns or redundant diagnostics. No impact on mortality was found. Additional insights into determinants of CCN success are required before broad implementation is warranted.
Open AccessComprehensive Cancer Networks in the Netherlands: how do they affect quality and costs of care for colon or pancreatic cancer? A retrospective cohort study
Objective: Concentration of care and collaborations between hospitals increasingly reorganise oncological care into Comprehensive Cancer Networks (CCNs), aiming to improve care outcomes and reduce costs. This study aims to evaluate the effect of four CCNs on healthcare cost and outcomes for patients with colon or pancreatic cancer. Design: We performed a retrospective cohort study based on claims data in the Netherlands. Data included patient characteristics, health insurance claims and healthcare activities. All costs were indexed to Euro 2023. We performed propensity score matching per CCN and applied regression models with a difference-in-difference design, adjusting for non-linear trends before the start of a CCN. Setting: The study was conducted within the Dutch healthcare system, analysing claims data representative of hospital-based cancer care. Participants: A total of 92 309 patients with colon cancer and 25 630 patients with pancreatic cancer were included. Patients were identified through health insurance claims between January 2013 and June 2021. Intervention: Implementation of four CCNs, which included structured collaboration between healthcare organisations. Follow-up duration was 2 years post-diagnosis. Outcome measures: Primary outcomes included 2-year oncological healthcare costs and 2-year mortality rate. Secondary outcomes involved care process indicators: referral rates and double diagnostics (an identical diagnostic activity performed within 4 weeks after referral to a secondary hospital). Results: For colon cancer, one CCN showed a significant decrease in 2-year oncological costs (−€1899). One CCN showed a significant decrease in referrals (−3.6%) and one a significant increase (+4.4%). No significant effect on 2-year mortality and double diagnostic activities was found. For pancreatic cancer, one CCN showed a significant decrease in 2-year oncological costs (−€3747) and one CCN showed a significant increase in double diagnostic activities (+8.6%). No significant effect on referrals and 2-year mortality was found. Conclusion: CCNs do not consistently reduce costs or affect referral patterns or redundant diagnostics. No impact on mortality was found. Additional insights into determinants of CCN success are required before broad implementation is warranted.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Supplementary tables and figure
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Supplementary tables and figure
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Methods from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Search strings for the literature search and the quality assesment tools
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Methods from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Search strings for the literature search and the quality assesment tools
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 23 (9) , 989-999
How to create value with constrained budgets in oncological care? A narrative review
As a result of an increasing focus on patient-centered care within oncology and more pressure on the sustainability of health-care systems, the discussion on what exactly constitutes value re-appears. Policymakers seek to improve patient values; however, funding all values is not sustainable. We collect available evidence from scientific literature and reflect on the concept of value, the possible incorporation of a wide spectrum of values in reimbursement decisions, and alternative strategies to increase value in oncological care. We state that value holds many different aspects. For reimbursement decisions, we argue that it is simply not feasible to incorporate all patient values because of the need for efficient resource allocation. We argue that we should shift the value debate from the individual perspective of patients to creating value for the cancer population at large. The different strategies we address are as follows: (1) shared decision-making; (2) biomarkers and molecular diagnostics; (3) appropriate evaluation, payment and use of drugs; (4) supportive care; (5) cancer prevention and screening; (6) monitoring late effect; (7) concentration of care and oncological networking; and (8) management of comorbidities. Important preconditions to support these strategies are strategic planning, consistent cancer policies and data availability.
- 1 September 2023
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 23 (9) , 989-999
Open AccessHow to create value with constrained budgets in oncological care? A narrative review
As a result of an increasing focus on patient-centered care within oncology and more pressure on the sustainability of health-care systems, the discussion on what exactly constitutes value re-appears. Policymakers seek to improve patient values; however, funding all values is not sustainable. We collect available evidence from scientific literature and reflect on the concept of value, the possible incorporation of a wide spectrum of values in reimbursement decisions, and alternative strategies to increase value in oncological care. We state that value holds many different aspects. For reimbursement decisions, we argue that it is simply not feasible to incorporate all patient values because of the need for efficient resource allocation. We argue that we should shift the value debate from the individual perspective of patients to creating value for the cancer population at large. The different strategies we address are as follows: (1) shared decision-making; (2) biomarkers and molecular diagnostics; (3) appropriate evaluation, payment and use of drugs; (4) supportive care; (5) cancer prevention and screening; (6) monitoring late effect; (7) concentration of care and oncological networking; and (8) management of comorbidities. Important preconditions to support these strategies are strategic planning, consistent cancer policies and data availability.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Supplementary tables and figure
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Supplementary tables and figure
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Supplementary tables and figure
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Supplementary tables and figure
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Methods from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Search strings for the literature search and the quality assesment tools
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Methods from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Search strings for the literature search and the quality assesment tools
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Methods from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Search strings for the literature search and the quality assesment tools
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Methods from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Search strings for the literature search and the quality assesment tools
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Comorbidities can have major implications for cancer care, as they might impact the timing of cancer diagnosis, compromise optimal care, affect treatment outcomes, and increase healthcare costs. Thus, it is important to comprehensively evaluate cancer comorbidities and examine trends over time. Here, we performed a systematic literature review on the prevalence and types of comorbidities for the five most common forms of cancer. Observational studies from Organisation for Economic Co-operation and Development countries published between 1990 and 2020 in English or Dutch that used routinely collected data from a representative population were included. The search yielded 3,070 articles, of which, 161 were eligible for data analyses. Multilevel analyses were performed to evaluate determinants of variation in comorbidity prevalence and trends over time. The weighted average comorbidity prevalence was 33.4%, and comorbidities were the most common in lung cancer (46.7%) and colorectal cancer (40.0%), followed by prostate cancer (28.5%), melanoma cancer (28.3%), and breast cancer (22.4%). The most common types of comorbidities were hypertension (29.7%), pulmonary diseases (15.9%), and diabetes (13.5%). After adjusting for gender, type of comorbidity index, age, data source (patient records vs. claims), and country, a significant increase in comorbidities of 0.54% per year was observed. Overall, a large and increasing proportion of the oncologic population is dealing with comorbidities, which could be used to inform and adapt treatment options to improve health outcomes and reduce healthcare costs.Significance:Comorbidities are frequent and increasing in patients with cancer, emphasizing the importance of exploring optimal ways for uniform comorbidity registration and incorporating comorbidity management into cancer care.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Comorbidities can have major implications for cancer care, as they might impact the timing of cancer diagnosis, compromise optimal care, affect treatment outcomes, and increase healthcare costs. Thus, it is important to comprehensively evaluate cancer comorbidities and examine trends over time. Here, we performed a systematic literature review on the prevalence and types of comorbidities for the five most common forms of cancer. Observational studies from Organisation for Economic Co-operation and Development countries published between 1990 and 2020 in English or Dutch that used routinely collected data from a representative population were included. The search yielded 3,070 articles, of which, 161 were eligible for data analyses. Multilevel analyses were performed to evaluate determinants of variation in comorbidity prevalence and trends over time. The weighted average comorbidity prevalence was 33.4%, and comorbidities were the most common in lung cancer (46.7%) and colorectal cancer (40.0%), followed by prostate cancer (28.5%), melanoma cancer (28.3%), and breast cancer (22.4%). The most common types of comorbidities were hypertension (29.7%), pulmonary diseases (15.9%), and diabetes (13.5%). After adjusting for gender, type of comorbidity index, age, data source (patient records vs. claims), and country, a significant increase in comorbidities of 0.54% per year was observed. Overall, a large and increasing proportion of the oncologic population is dealing with comorbidities, which could be used to inform and adapt treatment options to improve health outcomes and reduce healthcare costs.Significance:Comorbidities are frequent and increasing in patients with cancer, emphasizing the importance of exploring optimal ways for uniform comorbidity registration and incorporating comorbidity management into cancer care.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Supplementary tables and figure
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer
Supplementary tables and figure